Roopa Sethi, MD

Department of Psychiatry, Division Of Addiction Psychiatry, University of Kansas Medical Center, Kansas City, Kansas

24Articles
456.2KReads¹
2012–2026Active
41Collaborators
85Citations²

¹ Read counts for articles published before 2020 may include some non-human traffic.

² Citation counts provided by Crossref.

About

Roopa Sethi, MD, is affiliated with the Department of Psychiatry, Division of Addiction Psychiatry at the University of Kansas Medical Center. With publications spanning from 2012 to 2026, Dr. Sethi has contributed extensively to topics including addiction, schizophrenia and schizoaffective disorders, depression, neurology, pain management, suicide, and women's mental health. The work covers clinical aspects of opioid use disorder, buprenorphine treatment strategies, substance-related neurological effects, and emerging drug adulterants. Dr. Sethi frequently collaborates with colleagues such as Dheepthi Arakonam Ravishankar and Ryan McAllister in research published by Psychiatrist.com.

Publications

Review Article

Buprenorphine for Pain in Sickle Cell Disease

June 16, 2026

Buprenorphine is associated with improved functional outcomes as well as reduced ED visits, hospital admissions, and opioid use in patients with chronic pain related to sickle cell disease.

Satneet Singh, Amir Reza Akbari, Carlos Marín-López, et al

Case Report

Neurological Effects of Nitrous Oxide Abuse

July 3, 2025

A 31-year-old woman with a significant history of ketamine and N₂O addiction presented with a complicated range of neurological, neuropsychiatric, and psychiatric symptoms.

Ryan Asaukas, Spencer Silvey, Zeenat Habibullah, et al

Narrative Review

Fentanyl-Contaminated Oxycodone

November 9, 2023

The growing use of fentanyl-contaminated products is fueling the US opioid crisis. This study reviewed the rising prevalence of nonprescription fentanyl in counterfeit oxycodone, paying specific attention to oxycodone...

Roopa Sethi, Grace E. Hartmann

Narrative Review

Xylazine as a Fentanyl Adulterant in the US

October 31, 2023

Data obtained from studies between 2006 and 2022 indicate a rapidly increasing incidence of xylazine overdose in the United States, with overdose cases now being seen in 25 states.

Roopa Sethi, Caitlin E. Leconte

Systematic Review

Opioid Use Disorder and Its Treatment in the Elderly

January 10, 2023

OUD may be particularly problematic in the elderly due to age-related pain syndromes and comorbidities that increase the risk of side effects, overdose, and death. This review assessed the...

Roopa Sethi, Jaya Sri Konakanchi

Case Report

Rapid Microinduction of Buprenorphine in OUD

December 27, 2022

This is the case of a patient who was transitioned from agonist therapy with methadone to sublingual buprenorphine in an outpatient setting in just 3 days.

Roopa Sethi, Jaya Sri Konakanchi, Iryna Salapenka

Case Report

Sublingual Buprenorphine Induction and Maintenance for OUD

November 24, 2021

There are multiple factors to consider while initiating medications for opioid use disorder. Mr A is a 66-year-old man with a 17-year history of opioid use for pain management...

Roopa Sethi, Dheepthi Arakonam Ravishankar, Charn Grewal, et al

Case Report

Phenibut Dependence and Withdrawal

February 18, 2021

This case report demonstrates the use of benzodiazepines to alleviate the withdrawal symptoms of phenibut in a 26-year-old man who visited the emergency department multiple times.

Roopa Sethi, Dheepthi Arakonam Ravishankar, Radha Nagireddy

Case Report

Buprenorphine Induction Dosing in Elderly Opioid Use Disorder Patients

September 10, 2020

Here, read about the case of a 73-year-old man who developed hypotension, bradycardia, and possible respiratory depression following buprenorphine induction for opioid withdrawal.

Roopa Sethi, Annelise Chaparro, Dheepthi Arakonam Ravishankar

Case Report

Prednisone Therapy for Crohn's Disease Enhances Buprenorphine Metabolism

April 23, 2020

Could prednisone therapy for Crohn's disease enhance buprenorphine metabolism, ultimately leading to a false-negative urine drug screen? Read this interesting case report to find out more.

Roopa Sethi, Cooper D. Rodgers, Muhammad I. Gul

Case Report

Tapentadol: An Opioid of Abuse Acquired Online

February 20, 2020

Read a case report to find out more about Tapentadol and how it is often used for pain management, with low abuse potential.

Brant S. Ansley, Roopa Sethi

Review Article

Kratom: Friend or Foe?

January 30, 2020

Kratom has gained popularity as an inexpensive and accessible alternative to manage symptoms of opioid use disorder and pain. But, is it safe? This review provides the most up-to-date...

Roopa Sethi, Dheepthi Arakonam Ravishankar, Nguyen Hoang, et al

1 2 »

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Roopa Sethi, MD

About

Publications

Buprenorphine for Pain in Sickle Cell Disease